Juillerat Pascal, Grueber Maude Martinho, Ruetsch Roseline, Santi Giulia, Vuillèmoz Marianne, Michetti Pierre
Gastroenterology, Clinic for Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Crohn and Colitis Center, Gastro-entérologie Beaulieu SA, Lausanne, Switzerland.
Curr Res Pharmacol Drug Discov. 2022 Apr 28;3:100104. doi: 10.1016/j.crphar.2022.100104. eCollection 2022.
The number of available biological therapies have doubled over the last 10 years and the arrival of novel molecules (interleukin 23p19 inhibitors) is ongoing alongside the development of small molecules. As a result of this vast landscape of treatment, positioning advanced therapies (according to clinical situation, efficacy and safety) is of paramount importance to providing personalized, appropriate IBD treatment. In this publication the recent available literature is summarized for practical integration into clinical practice including comparative efficacy data, patient and disease demographics. We refer to recent publications and expert opinion in order to facilitate the decision making process of positioning biologicals IBD treatment.
在过去10年中，可用的生物疗法数量增加了一倍，新型分子（白细胞介素23p19抑制剂）不断涌现，同时小分子药物也在不断发展。由于治疗手段如此多样，根据临床情况、疗效和安全性来定位先进疗法对于提供个性化、合适的炎症性肠病（IBD）治疗至关重要。在本出版物中，总结了近期可得的文献，以便实际应用于临床实践，包括比较疗效数据、患者和疾病特征。我们参考近期的出版物和专家意见，以促进IBD生物治疗定位的决策过程。
